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1  | INTRODUC TION
Chromatin structure dynamics regulate many aspects of cellular pro-
cesses.1,2 Histone tail modifications have a major role in determining 
structural and functional changes through a sophisticated signal-
ing code, which is interpreted by a complex network of interacting 
proteins.3 Histone methylation in particular has been shown to be a 
key factor in transcription regulation and DDR.4 Mono- methylation, 
di- methylation and tri- methylation can be catalyzed by specialized 
histone methyl transferases at specific lysine (K) and arginine (R) res-
idues on histone tails and erased by specific histone demethylases 
(HDM). Two families of HDM have been identified in eukaryotes: the 
LSD1 family and the Jumonji C- domain- containing family. Jumonji 
C- domain- containing HDM (JHDM) are Fe2+ and α- ketoglutarate- 
dependent hydroxylases. They are divided into 7 phylogenetically 
distinct subfamilies (JHDM1- 3, JARID, PHF2/PHF8, UTX/UTY 
and JmjC domain only), with each group sharing a common set of 
substrates.5,6
Jumonji C- domain- containing HDM have an important role in 
cancer epigenetics7 and, among them, those capable of demethylat-
ing specifically H3K4 (JARID 1A- 1D) look particularly interesting as 
potential therapeutic targets.8,9
Indeed, JARID1A was found to be upregulated in gastric10 and 
cervical cancer.11 In particular, in gastric cancer, Zeng and colleagues 
observed that JARID1A is responsible for the repression of p16, p21 
and p27.10
In parallel, JARID1B (previously known as PLU- 1), was initially 
identified as a markedly upregulated gene in breast cancer12 and 
later found overexpressed in prostate,13 bladder and lung cancer14 
and melanomas.15 More importantly, Yamane and colleagues found 
that downregulation of JARID1B in MCF7 breast cancer cell line 
decreased cell growth.16 This was confirmed in an in vivo mouse 
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JARID1B/KDM5B histone demethylase's mRNA is markedly overexpressed in breast 
cancer tissues and cell lines and the protein has been shown to have a prominent role 
in cancer cell proliferation and DNA repair. However, the mechanism of its post- 
transcriptional regulation in cancer cells remains elusive. We performed a computa-
tional analysis of transcriptomic data from a set of 103 breast cancer patients, which, 
along with JARID1B upregulation, showed a strong downregulation of 2 microRNAs 
(miRNAs), mir- 381 and mir- 486, potentially targeting its mRNA. We showed that both 
miRNAs can target JARID1B 3′UTR and reduce luciferase's activity in a complementarity- 
driven repression assay. Moreover, MCF7 breast cancer cells overexpressing JARID1B 
showed a strong protein reduction when transfected with mir- 486. This protein's de-
crease is accompanied by accumulation of DNA damage, enhanced radiosensitivity 
and increase of BRCA1 mRNA, 3 features previously correlated with JARID1B silenc-
ing. These results enlighten an important role of a miRNA’s circuit in regulating 
JARID1B's activity and suggest new perspectives for epigenetic therapies.
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model, in which shJARID1B led to suppression of mammary tumor 
growth.16,17 Analogous results were obtained in bladder and lung 
cancer cell lines.14 Taken together, these observations lead to the 
conclusion that JARID1B could be a crucial player in regulating the 
development and growth of certain types of cancer. Nonetheless, 
JARID1B is downregulated in triple negative breast cancer subtype 
cell lines as MDA- MB- 231. This negative modulation was proposed 
to be functional to cancer cell migration, invasiveness and metastatic 
potential, which characterize this subtype of aggressive breast can-
cer cell line.18 Thus, depending on the cellular environment, JARID1B 
might be considered as an oncogene or a tumor suppressor.
Moreover, the JARID1 subfamily has recently been confirmed to 
be deeply involved in the mechanism of DNA double strand break 
(DSB) repair (DDR). Although H3K4me3 was previously suggested 
to have a positive role in DNA repair,19 more recent observations 
by Li and colleagues20 suggest that it is H3K4me3 removal, rather 
than its presence, that facilitates DDR protein recruitment: JARID1B 
is, in fact, specifically enriched in DNA damage sites after irradia-
tion, in a PARP1- dependent and macroH2A1.1- dependent mecha-
nism. Interestingly, recruitment and catalytic activity of JARID1B 
are both required for local H3K4me3 demethylation, which allows 
for Ku70/80 or BRCA1 association to the site of damage, respec-
tively, in non- homologous end joining and homologous recombina-
tion (HR) pathways.20 In parallel, JARID1B- depleted irradiated cells 
displayed an enhanced γ- H2AX signal, along with a G1 arrest and a 
phosphorylated- p53 (a downstream effector of ATM/ATR- mediated 
CHK1/CHK2 activation). More interestingly, p53 activation and 
H2AX phosphorylation were also present in non- irradiated cells, 
suggesting that JARID1B depleted cells are more prone to sponta-
neous DNA breaks.20 In addition to this, Gong and colleagues also 
described a similar role for JARID1A: this protein is recruited to the 
site of damage in a PARP1- dependent manner and its demethylating 
activity on pre- existing H3K4me3 is required for ZMYND8 recruit-
ment to the site of damage,21 which, in turn, allows NuRD complex 
association to initiate HR- related remodeling events.22,23 In partial 
contrast with these observations, Penterling and colleagues sug-
gested that JARID1A's role in DDR is not dependent on its catalytic 
activity. However, depletion of this protein enhances cells’ sensi-
tivity to irradiation- induced death. The authors proposed that this 
is probably because demethylating activity at the sites of damage 
is mostly carried out by JARID1B, as observed in Li et al (2014).20 
Instead, sensitivity to ionizing radiation observed upon JARID1A de-
pletion might be due to concurrent histone hyperacetylation.24
MicroRNAs (miRNAs) are endogenous small non- coding RNAs 
that regulate gene expression by binding to the 3′ UTR of the mRNA 
targets.25 Increasing evidence shows a deregulation of miRNA ex-
pression in human cancer, indicating that they are potential biomark-
ers for cancer diagnosis and prognosis, as well as therapeutic targets 
or tools.26,27 In this work, we demonstrate that one of the mostly 
downregulated miRNAs in human breast cancer, miR- 486, regulates 
JARID1B expression in human cell lines. In addition, we show that 
miR- 486 induced JARID1B downregulation is accompanied by accu-
mulation of DNA damage and enhanced radiosensitivity.
2  | MATERIAL S AND METHODS
2.1 | Computational analysis of breast cancer 
patients’ transcriptome
Gene expression data was obtained for the TCGA public database 
(cancergenome.nih.gov). For this research, datasets of mRNAs and 
small RNAs (RNA- Seq) from breast cancer patients were used. 
Computational analysis was performed using R version 3.4.3. Only 
the subset of data related to samples that had both normal and can-
cer counterparts was taken into consideration, to assess differences 
in gene expression related to single patients. For this reason, all data 
related to “cancer- only” or “normal- only” samples (without a coun-
terpart) were discarded from the analysis. The same principle was 
used to compare mRNA and miRNA data; therefore, the actual sub-
set of patients used was composed of those who had all 4 kinds of 
data (mRNA normal, mRNA cancer, miRNA normal and miRNA can-
cer). The lists of the significant modulated mRNAs/miRNAs was ob-
tained by applying the following criteria: (i) mRNAs/miRNAs whose 
expression profiles were characterized by an interquartile range 
(IQR) value that stood under the 10th percentile of the IQR value 
distribution were discarded; (ii) mRNAs/miRNAs with a foldchange 
<2 were discarded; and (iii) mRNAs/miRNAs with a false discovery 
rate (FDR) >.01 were discarded. These lists were cross- checked to 
identify differentially expressed miRNAs that could be targeting 
differentially expressed mRNAs of interest. Data for miRNA- mRNA 
targeting prediction was downloaded from TargetScan.org.
2.2 | Kaplan- Meier
We performed Kaplan- Meier analyses28 by using clinical and expres-
sion data provided by the TCGA portal relating to 1062 patients af-
fected by breast cancer. The patient samples are split into 2 groups 
(low- expression and high- expression) according to the expression 
level of a given transcript with respect to distribution of the expres-
sion values of all other transcripts. In particular, low- expression 
and high- expression groups refer to patients with expression lev-
els lower than or greater than the 50th percentile, respectively. A 
log- rank test was performed to evaluate the P- value associated with 
each switch gene: the lower the P- value, the better the separation 
between the prognoses of the 2 groups.
2.3 | DNA constructs
miRNA overexpression plasmids (pSP65/U1- miR- 381- 3p, pSP65/
U1- miR- 486- 5p miRNA OE plasmids) were obtained by amplifying 
miR- 381- 3p and miR- 486- 5p genomic regions, containing approxi-
mately 100 nt upstream and 100 nt downstream of the miRNA stem- 
loop sequence (http://www.mirbase.org/). The PCR fragments were 
cloned downstream of the U1 promoter of a pSP65/U1vector ob-
tained, as previously described.29
Transfected MCF7 cells displayed a high fold- increase in miRNA 
expression (data not shown). Jarid1B 3′ UTR from human genomic 
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DNA was amplified and cloned into the Xho1 and EcoR1 unique 
sites downstream of the Renilla coding sequence of Psi- CHECK- 2 
vector (Promega, Madison, WI, USA) (Psi- CHECK/Jarid1B). To gen-
erate Jarid1B 3′ UTR mutant constructs, mutations at miR- 381- 3p 
(Psi- CHECK/Jarid1B 381 mut) or miR- 486- 5p (Psi- CHECK/Jarid1B 
486 mut) seed binding sites were introduced into the Jarid1B 3′ UTR 
using synthetic oligonucleotides by generating partially complemen-
tary PCR fragments. These fragments were used as templates for 
PCR to generate complete mutated Jarid1B 3′ UTR fragments, and 
further cloned as described for wild- type 3′ UTR. All constructs have 
been checked by sequencing. See Table S1 for primer sequences.
2.4 | Cell culture and transfection
Human breast cancer HEK293, MCF7, T47D and MDA-MB-231 cells 
were a gift from Dr Lucia Gabriele (Istituto Superiore di Sanità, Rome, 
Italy), who purchased them from ATCC and maintained them in cul-
ture. Cells were cultured for, at most, 10-12 passages, then replaced 
by cells from early passages, kept in liquid nitrogen since collection. 
The presence of mycoplasma was checked every 6 months using a 
Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO, USA).
Cells were grown in high- glucose DMEM medium plus FBS, 
1 mmol L−1 L- glutamine, 100 U/mL penicillin and 100 μg/mL strepto-
mycin (Thermo Fisher Scientific, Waltham, MA, USA). For RNA and 
protein analysis, transfections were performed at 70% confluency 
using Lipofectamine 2000 Reagent, according to the manufacturer‘s 
protocol (Thermo Fisher Scientific). Cells were transfected in 6- well 
plates with 4 μg of miRNA overexpression plasmids and cell lysates 
were prepared at 48 and 72 hours after plasmid transfections for 
subsequent analysis as specified. Transfected MCF7 cells displayed 
a high fold- increase in miRNA expression (data not shown).
2.5 | RNA extraction and quantitative RT- PCR
Total RNA extraction from transfected cells was performed using 
an miRNeasy Mini Kit, according to the manufacturer's guidelines 
(Qiagen, Germantown, MD, USA). Quantitative RT- PCR analysis of 
miRNAs was done by miScript II RT- PCR kit (Qiagen) with HiFlex 
buffer allowing retrotranscription of both mRNA and miRNA spe-
cies. Relative quantification of gene expression was conducted 
with the Applied Biosystems 7500 Real- Time PCR System and 
data analysis was performed using the comparative ΔΔCT method. 
Endogenous genes used as internal controls for miRNA and mRNA 
were U6 snRNA and GAPDH mRNA, respectively.
2.6 | Luciferase assay
Psi- CHECK- 2 vector (Promega) containing both Renilla and firefly 
luciferase genes was used to clone JARID1B 3′UTR downstream of 
the Renilla gene (psi- CHECK/Jarid1B). For transfection efficiency, 
the Renilla luciferase signal was normalized upon firefly signal. To 
perform luciferase assays, cells were seeded on 96- well plates, co- 
transfected with both luciferase containing plasmid (psi- CHECK/
Jarid1B and empty psi- CHECK) and miR- OE plasmids (pSP65/U1- 
miR- 381- 3p, pSP65/U1- miR- 486- 5p). Luciferase assays were per-
formed 24 and 48 hours after transfection, using the Dual- Luciferase 
Reporter Assay System (Promega), according to protocol guidelines. 
To evaluate firefly (reference) activity, 100 μL of Luciferase Assay 
Reagent II (LAR II) was added to each well and luminescence was 
measured using a Wallac VICTOR2 1420 (Perkin-Elmer, Waltham, 
MA, USA) plate reader. Renilla luciferase activity was expressed 
relatively to firefly activity.
miRNA effect on psi- CHECK/Jarid1B reporter expression was 
evaluated as a percentage of luciferase activity from pSP65/U1- 
miR- 381- 3p or pSP65/U1- miR- 486- 5p transfected cells compared 
to control vector (pSP65/U1) transfected cells. Data shown is the 
result of at least 4 independent experiments.
2.7 | Protein expression analysis
Transfected cells were harvested after 48 hours, DMEM was re-
moved, cells were washed with Dulbecco's PBS (Carlo Erba Reagents) 
and then resuspended in 60 μL RIPA buffer (Sigma- Aldrich) with 
protease inhibitor cocktail (Complete, EDTA-free Protease Inhibitor 
Cocktail, Roche, Basel, Switzerland). Cell lysates were obtained ac-
cording to the manufacturer's guidelines and stored at −20°C.
Western blot analysis was used to evaluate the JARID1B amount. 
For each sample, 40 μg of proteins were run on an 8% denaturing 
PAGE to resolve both 180 kDa JARID1B and 43 kDa actin that 
was used as loading control. Histones were resolved on a 12% 
PAGE, using 20 μg of RIPA extracted total proteins. Transfer effi-
ciency was verified via ponceau staining (Sigma Diagnostics). Filters 
were hybridized with rabbit anti- JARID1B (1:200, Cell Signaling 
Technology, Cat#3273 RRID: AB_1264191), rabbit anti- actin 
(1:1000, Sigma- Aldrich, Cat#A2066 RRID: AB_476693), rabbit anti- 
H3K4me3 (1:1000. Active Motif, Cat#39915 RRID: AB_2687512), 
rabbit anti- H2AX (1:1000, Cell Signaling Technology, Cat#7631, 
RRID: AB_10860771) and rabbit anti- Phospho- H2AX (1:1000, Cell 
Signaling Technology, Cat#9718, RRID: AB_2118009) at 37°C over-
night. Goat anti- rabbit HRP conjugate (1:10 000, Thermo Fisher 
Scientific Cat#31460, RRID: AB_228341) was used as a secondary 
antibody. For quantitative analysis, western blots were analyzed with 
a ChemiDoc XRS+ Imaging System (Bio- Rad, Hercules, CA, USA). 
The signal for each protein was normalized to actin detected on the 
same blot, and ratios with average control values were determined.
2.8 | Chromatin immunoprecipitation assay
ChIP assay was performed using the MAGnify Chromatin 
Immunoprecipitation System (Thermo Fisher Scientific). Then, 24- 
hours post- transfection, MCF7 cells were prepared according to 
the manufacturer's instructions. DNA- bound protein was immune- 
precipitated using the following antibodies: anti- JARID1B (1:50, Cell 
Signaling Technology, Cat#3273 RRID: AB_1264191), anti- H3K4me3 
(1:50. Cell Signaling Technology, Cat# #9751 RRID: AB_2616028) 
or anti- IgG (as negative control provided by kit). PCR amplification 
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(35 cycles) was performed on 1 μL of input or 5 μL of DNA immuno- 
precipitated with anti- JARID1B, anti- H3K4me3 or anti- IgG, using 
DreamTaq DNA Polymerase (Thermo Scientific) and the following 
primers:
BRCA1 Fw 5′- TAAGCCGCAACTGGAAGAGT- 3′
BRCA1 Rv 5′- CAGAAAGAGCCAAGCGTCTC- 3′
ACTB Fw 5′- GCCGGGACCTGACTGACTA- 3′
ACTB Rv 5′- TGGTGATGACCTGGCCGT- 3′
2.9 | Flow- cytometry
Flow- cytometry analysis of DNA content was performed using an 
EPICS xl flow- cytometer (Beckman- Coulter). At the indicated times 
from transfection, MCF7 cells were trypsinized, pelleted, washed 
with PBS and, finally, resuspended in PBS containing .1% Triton- 
X- 100 (AppliChem) and 40 μg/mL propidium iodide (Sigma-Aldrich). 
The samples were incubated for 20 min at 37°C and then analyzed, 
acquiring 10 000 events for each sample. Acquired data were ana-
lyzed using the WinMDI software by Joe Trotter, available at http://
facs.scripps.edu
2.10 | Irradiation and clonogenic assay
Cells were X- ray irradiated at 200 V and 6 mA (Gilardoni MLG 
300/6- D) 24 hours post- transfection to produce an equivalent ab-
sorbed dose of 1 cGy/s. X- ray and sham- irradiated cells were then 
incubated for 4 hours. Cells were harvested, seeded on 60- mm wells 
at a density of 103 cells/well and incubated for 14 days. Fixing and 
staining of cell colonies were performed in .3% Methylene Blue, 80% 
ethanol solution for 30 minutes and extensively washed with ddH2O. 
Colorimetric images were taken using the ChemiDoc XRS+ Imaging 
System (Bio- Rad). Colonies were counted using Fiji software,30 ap-
plying the “Find maxima” function and a background noise threshold 
of 3000. Proliferative capacities of each experimental group (pSP65/
U1, pSP65/U1- miR- 381- 3p and pSP65/U1- miR- 486- 5p) was then 
calculated as the relative number of colonies for each radiation dose 
(1, 3 and 10 Gy), relativel to sham- irradiated samples, to normalize 
any radiation- independent effects of miRNAs on cells.
3  | RESULTS
3.1 | JARID1B/KDM5B upregulation in breast 
cancer patients correlates with a downregulation of 
predicted miRNAs targeting it
We performed a computational analysis of transcriptomic data from 
a set of 103 breast cancer patients (Cancer Genome Atlas public 
database). The analysis revealed that in tumor tissues, almost 4000 
genes are modulated at least 2- fold. Among these, several epigenetic 
players were found to be differentially expressed (summarized in 
Table 1). As expected from previous observations, JARID1B/KDM5B 
is upregulated in breast cancer patients, showing a 2- fold increase, 
with highly statistical significance (FDR = 1.48 × 10−25). All the 
epigenetic modifiers reported in Table 1 are genes previously known 
to be modulated in breast cancer (DNMT3B,31 EZH2,32 HDAC4,33 
HOTAIR,34 KAT2B,33 KDM5B,12 MEF2C and35 SMYD334), except 
for SMYD1/KMT3D, which was never reported to be modulated in 
this type of tumor. Interestingly, this latter gene is among the most 
repressed ones (−97.4% of expression with respect to normal tissue, 
FDR = 4.46 × 10−28). Next, we analyzed the list of significantly down-
regulated miRNAs to identify those potentially targeting JARID1B. 
According to TargetScan (http://www.targetscan.org), 12 miRNAs 
(reported in Table S2) showed the required sequence complemen-
tarity with JARID1B 3′UTR region. We focused on the 2 most re-
pressed ones, as they are, in principle, the best candidates that could 
account for a JARID1B modulation in breast cancer tissue: miR- 
486- 5p is found to be almost completely silenced (log2- foldchange 
= −3.97, FDR = 3.27 × 10−31) and it is actually the most repressed 
miRNA of the whole analysis, while miR- 381- 3p shows a 3- fold de-
crease (log2- foldchange = −1.554, FDR = 2.91 × 10−32). miR- 486- 5p 
displays a higher sequence complementarity with the JARID1B 
3′UTR with respect to miR- 381- 3p, that extends outside the seed 
region, suggesting a stronger targeting efficacy (Figure S1). JARID1B 
is also a bona fide target of both miRNAs according to microRNA.
org (http://www.microrna.org) prediction. The box plot in Figure 1A 
summarizes JARID1B, miR- 381- 3p and miR- 486- 5p modulation in 
breast cancer samples with respect to normal tissues: in absolute 
figures, miR- 381- 3p is generally less expressed than miR- 486- 5p in 
normal conditions, while their expression is almost equalized in can-
cer cells. In particular, miR- 486- 5p shows a wide variability in the 
level of expression in normal conditions, that is sensibly reduced in 
cancer conditions, suggesting the emergence of a regulative mecha-
nism that is not operating in normal conditions.
A scatter plot of miR- 381- 3p vs JARID1B expression (Figure 1B) 
reveals that normal samples form a separated cluster with respect to 
cancer samples. Correlation between miRNAs and their target protein 
levels does not always affect mRNA levels, as the canonical miRNA 
TABLE  1 Modulated genes coding for epigenetic players in 
breast cancer tissues
Gene FDR log2 fold change Molecular function
EZH2 5.25E- 32 2.084353478 H3K27 
methylation
HOTAIR 1.24E- 08 1.94264031 PRC2 interactor
SMYD3 7.12E- 21 1.213517762 H3K4 methylation
DNMT3B 3.86E- 15 1.084809605 DNA de novo 
methylation
KDM5B 1.48E- 25 1.019012074 H3K4me2/3 
demethylation
HDAC4 2.57E- 26 −1.134060683 Histone 
deacetylation
MEF2C 1.38E- 20 −1.162203015 HDAC4 interactor
KAT2B 3.77E- 25 −1.324736764 Histone acetylation
SMYD1 4.46E- 28 −5.279628314 H3K4 methylation
FDR, false discovery rate.
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mode of action is limited to the repression of translation rather than 
leading to destabilization of mRNAs of their targets. However, it is 
possible that, in cancer cells, both phenotypes (miRNA downregu-
lation and JARID1B mRNA upregulation) might arise independently. 
Concerning miR- 381- 3p, the Pearson coefficient calculated on the 
whole dataset suggests that its expression is anti- correlated with 
that of JARID1B (Figure 1B, ρ = −.4); however, this anti- correlation is 
not conserved in the 2 separated subsets of normal- only and cancer- 
only samples, meaning that, even though breast cancer cells display a 
concomitant JARID1B upregulation and miR- 381- 3p downregulation, 
these 2 alterations might arise independently from each other.
In contrast, the miR- 486- 5p scatter plot reveals a similar sample 
clustering (Figure 1C). However, in this case, its anti- correlation might 
effectively account for a regulative mechanism, as it is preserved in 
the normal- only subset, while it is lost in the cancer- only subset, sug-
gesting that in physiological conditions, the miRNA could be engaged 
in downregulating JARID1B mRNA accumulation but if its concentra-
tion is lower than a threshold level (as it might be in breast cancer), 
this mechanism is no longer relevant. Once again, anti- correlation be-
tween a miRNA and its target mRNA does not always mean that there 
is a functional link between the 2 levels of expression: it is more likely 
an additive effect rather than a causative one. Therefore, it is possible 
that miR- 486- 5p contributes to the post- transcriptional downregula-
tion of JARID1B mRNA in normal conditions and that, in contrast, in 
cancer cells, this cooperative repression is lost, allowing higher levels 
of JARID1B mRNA to produce higher levels of JARID1B protein.
We next analyzed the association of the 2 miRNAs’ expression 
level with patient survival. The Kaplan- Meier diagram in Figure 1D 
F IGURE  1  JARID1B/KDM5B, miR- 381- 3p and miR- 486- 5p expression level in breast cancer patients and association of their expression 
level with patients’ survival. A, Box plot showing miR- 381- 3p, miR- 486- 5p and JARID1B/KDM5B expression in normal (blue) and cancer 
(yellow) subsets. Statistical significance was assessed according to 2- tailed paired Student's t test, ****P < .0001. B, Scatter plot of miR- 381- 
3p vs JARID1B/KDM5B expression in both normal (blue) and cancer (yellow) samples. Pearson coefficients are calculated for total (ρ = −.40), 
normal- only (ρN = .40) and cancer- only (ρC = .02) datasets and respective correlation lines (black, blue, yellow) are reported in the plot. 
C, Scatter plot for miR- 486- 5p vs JARID1B/KDM5B expression in both normal (blue) and cancer (yellow) samples. Pearson coefficients 
are calculated for total (ρ = −.72), normal- only (ρN = −.65) and cancer- only (ρC = −.14) datasets and respective correlation lines (black, blue 
and yellow) are reported in the plot. D, Kaplan- Meier diagram showing survival for patients with higher (>50th percentile, cyan) or lower 
(<50th percentile, magenta) expression of miR- 381. E, Kaplan- Meier diagram showing survival for patients with higher (>50th percentile, 
cyan) or lower (<50th percentile, magenta) expression of miR- 486. F, Kaplan- Meier diagram showing survival for patients with higher (>50th 
percentile, cyan) or lower (<50th percentile, magenta) expression of JARID1B
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shows that patients with higher expression (>50th percentile) of miR- 
381 have a significantly longer survival (P = .05) than those with a 
lower expression, while no significant effect is observed for miR- 486 
(Fig. 1E). This could be due to the fact that while a consistent part of 
the cancer samples shows expression levels of miR- 381 comparable 
to the control population, most of the tumors have a very low ex-
pression level of miR- 486 compared to the normal population, mak-
ing internal differences irrelevant for regulating the JARID1B protein 
level. The JARID 1B mRNA level itself does not show an impact on 
survival (Fig. 1F), contrary to what has recently been observed for its 
protein level, which generally negatively correlates with survival,36 
confirming that post- transcriptional regulation is crucial.
3.2 | Validation of the inhibitory effect of miR- 381- 
3p and miR- 486- 5p on JARID1B translation
Until very recently,37 no miRNAs showing sequence complemen-
tarity with JARID1B 3′UTR had been experimentally proven to be 
able to target its mRNA in vivo and reduce luciferase's activity in a 
complementarity- driven repression assay.
To address whether miR- 381 and miR- 486 could effectively ex-
ploit their function by targeting complementary regions on JARID1B 
mRNA, the 3′UTR region of this gene was used as a recombinant 
3′UTR for Renilla luciferase gene expressed by a reporter vector. The 
resulting construct was introduced by transfection in HEK 293 cells. 
We therefore transfected HEK 293 cells with plasmids overexpress-
ing miR- 381- 3p and miR- 486- 5p, pSP65/U1- miR- 381- 3p, pSP65/U1- 
miR- 486- 5p, respectively. This assay only accounts for a qualitative 
evaluation of the molecular complementarity- driven targeting mech-
anism performed by miRNAs, as the amount of ectopically- expressed 
miRNAs obtained via U1 promoter does not correspond to any phys-
iological or cancerous conditions reported. However, the results ob-
tained (Figure 2A) clearly demonstrate that upon overexpression of 
both miRNAs, Renilla relative activity is decreased with respect to 
pSP65/U1 empty plasmid- transfected cells. The statistical signifi-
cance of this effect is high and reproducible, both at 24 and 48 hours, 
with the exception of the 24- hour post- transfection effects of miR- 
381, whose modulation is only barely significant (P = .053). As a con-
trol, we produced constructs carrying the JARID1B mRNA 3′UTR 
region with mutated seeds for miR- 381- 3p and miR- 486- 5p, respec-
tively. Transfection of HEK 293 cells carrying these constructs with 
the corresponding miRNAs did not cause any significant reduction of 
luciferase activity (Figure 2B). These data provide molecular evidence 
that both miR- 381- 3p and miR- 486- 5p are able to target JARID1B 
3′UTR and, presumably, impair its translation into protein.
3.3 | MiR- 381- 3p and miR- 486- 5p overexpression 
impairs JARIDB protein accumulation in MCF7 breast 
cancer cells
To prove the role of miRNAs in regulating JARID1B translation in 
breast cancer, we transfected them in the breast cancer cell line 
MCF7 that overexpresses JARID1B.38,39
Protein samples from 48- hour post- transfection cells were 
used to assess JARID1B protein levels by western blot analysis 
(Figure 3A). The results (summarized in Figure 3B) show that both 
miRNAs could account for the suggested repressive mechanism: 
overexpression of miR- 381- 3p reduces JARID1B's protein level by 
almost 40%, while miR- 486- 5p seems to be even more effective, as 
it reduces the protein level by around 60%. Nonetheless, H3K4me3 
(JARID1B substrate) levels in bulk chromatin, are not significantly 
affected by JARID1B knockdown (Figure 3C), suggesting that this 
epigenetic regulator is probably not involved in a continuous global 
F IGURE  2 miR- 381- 3p and miR- 486- 5p target JARID1B 3′UTR. 
Renilla activity (normalized on firefly luciferase activity) measured 
from psiCHECK- 2 and pSP65/U1- miR co- transfected HEK 293 cells 
at 24 and 48 h post- transfection, n = 6. Data are represented as the 
mean ± SD of Renilla/Firefly activity. Statistical significance was 
assessed according to a 2- tailed Student's t test, **P < .01
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histone demethylation in breast cancer cells but rather in a more 
specific activity. However, we cannot rule out the possibility that 
a residual amount of the protein could still be able to carry out bulk 
chromatin demethylation to the same extent.
3.4 | Overexpression of miR- 381- 3p and miR- 486- 
5p does not affect the levels of JARID1B mRNA
Using quantitative RT- PCR, the levels of JARID1B mRNA were 
measured in MCF7 cells transfected with pSP65/U1- miR- 381- 3p, 
pSP65/U1- miR- 486- 5p miRNA overexpressing plasmids. The re-
sults (Figure 3D) revealed that miRNAs do not induce any signifi-
cant effect on JARID1B mRNA accumulation, as its levels appear 
unchanged in miRNA overexpressing cells with respect to control 
conditions.
While an effect of miRNAs at protein level but not at mRNA level 
is generally observed in mammalian cells,40 these results suggest 
that anti- correlation between miRNAs and JARID1B transcript lev-
els discussed above cannot be read as a causal relationship: in other 
words, JARID1B mRNA upregulation in cancer is not connected to 
a lack of these specific miRNAs. However, one possible speculation 
is that these two phenotypes arise independently in cancer cells as 
a reinforcing mechanism that, by repressing JARID1B expression at 
both transcriptional and post- transcriptional levels, results in a pro-
liferative advantage for them.
3.5 | JARID1B target gene BRCA1 is upregulated 
upon miR- 486- 5p overexpression
JARID1B has been shown to be involved in regulating the mRNA 
accumulation of important regulatory genes. In particular, its re-
pressing activity on BRCA1 with important functional implications 
has been demonstrated in several breast cancer cell lines, including 
MCF7.18
We therefore tested whether the effects of miR- 381- 3p and 
miR- 486- 5p overexpression on JARID1B abundance in MCF7 cells 
could influence BRCA1 mRNA accumulation.
The results shown in Figure 3 confirm that both miR- 381- 3p and 
miR- 486- 5p overexpression increase the amount of BRCA1 mRNA 
(1.6- fold and 2.8- fold, respectively) 48 hours from transfection.
We also tested other genes that were previously shown to be 
modulated when JARID1B was downregulated by siRNA.38,39 In par-
ticular, MT1F is significantly repressed, as previously shown,37 while 
CAV1 is only slightly and not significantly induced (Figure S2).
To test the effects of miR- 486- 5p overexpression on JARID1B 
association in BRCA1 promoter and H3H4 tri- methylation, we per-
formed ChIP experiments (see Materials and Methods). Figure 3F 
shows that JARID1B is binding to BRCA1 promoter in MCF7 trans-
fected with pSP65/U1 empty plasmid, as previously shown,16 while 
no association with the control amplicon (ACTB exon5) is detected. 
When the cells are transfected with the pSP65/U1- miR- 486- 5p 
F IGURE  3 miR- 381- 3p and miR- 486- 5p overexpression impairs JARID1B mRNA translation without affecting JARID1B mRNA levels 
and upregulates the JARID1B target gene BRCA1. A, Representative western blotting image of JARID1B protein and H3K4me3 levels in cell 
lysate from MCF7 cells 24 h after transfection with control pSP65/U1, pSP65/U1- miR- 381- 3p or pSP65/U1- miR- 486- 5p. B and C, Relative 
quantification of JARID1B protein (B) and H3K4me3 (C) levels in western blotting analysis, n = 7. Data are represented as the mean ± SD of 
JARID1B or H3K4me3 levels relative to actin. Statistical significance was assessed according to 2- tailed paired Student's t test, **P < .01. 
D and E, Quantitative RT- PCR analysis of JARID1B (D) and BRCA1 (E) mRNA levels from MCF7 cells 48 and 72 hours after transfection 
with control pSP65/U1, pSP65/U1- miR- 381- 3p or pSP65/U1- miR- 486- 5p, n = 4. JARID1B and BRCA1 raw data (Ct) were normalized on 
GAPDH expression levels (ΔCt) as endogenous control and ΔΔCt was calculated with respect to control transfection (pSP65/U1). Data 
are represented as the mean ± SD. Statistical significance was assessed according to 2- tailed Student's t test, **P < .01. F, ChIP assay (see 
Materials and Methods) to test JARID1B association and H3K4 trimethylation level at the BRCA1 promoter. The location of the primers used 
for the PCR amplification of the BRCA1 proximal promoter segment is reported in the map at the top. The ACTB exon V region is used as a 
negative control for JARID1B binding and H3K4 tri- methylation
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miRNA overexpressing plasmid, a reduction in the JARID1B associ-
ation is evident. In the same ChIP experiments, we did not observe 
an evident increase of H3K4me3 upon miR- 486- 5p overexpression. 
This is not surprising because JARID1B binds to the BRAC1 promoter 
in tight association with the NURD complex and cooperates with it in 
transcriptional repression.18 Recovery of H3K4 trimethylation could 
be dispensable for the observed transcriptional de- repression or de-
layed in time.
3.6 | Overexpression of miR- 381- 3p and miR- 486- 
5p affect cell cycle dynamics
BRCA1 repression is a crucial event in breast cancer to escape cell 
cycle control. The protein is involved in promoting G1/S arrest 
through both P53- dependent or P53- independent mechanisms.41 
We therefore tested the effects of miR- 381- 3p and miR- 486- 5p on 
cell cycle dynamics by cytofluorimetric analysis. The results reported 
in Figure S3 show that transfection with miR- 381- 3p and miR- 486- 5p 
causes a significant increase in G1/G0 cell population and a decrease 
in S population at 24 hours, which are still detectable at 48 hours 
(statistically significant only for miR- 381- 3p). These results are co-
herent with the increase in BRCA1 expression caused by miRNA 
transfection, although additional regulators could be involved. On 
the other hand we do not observe any significant increase in the 
subG1 population, which could be diagnostic of apoptotic effects. 
This is not surprising because MCF7 cells are apoptosis- resistant due 
to lack of Caspase- 3.42 Therefore, we did not perform more specific 
apoptosis assays.
3.7 | miR- 381- 3p and miR- 486- 5p overexpression 
increases cells sensitivity to radiation and 
accumulation of DBS in MCF7 cells
Given the emerging role of JARID1B as a key player of DDR, we hy-
pothesize that lowering its expression could impair, to some extent, 
the ability of the cell to overcome DNA double- strand breaks. 
Therefore, JARID1B targeting by miRNAs should, in principle, sen-
sitize cells to X- ray irradiation- induced DNA damage and result in a 
greater proportion of cells unable to proliferate.
This rationale was used to test the miRNA effects and the results 
are summarized in Figure 4.
In Figure 4A, both miR- 381- 3p and miR- 486- 5p were observed 
to decrease the fraction of surviving cells able to proliferate: for 1 
and 3 Gy irradiation doses, proliferative capacity, measured as the 
fraction of plated cells able to proliferate and give rise to colonies 
F IGURE  4 MiR- 381- 3p and miR- 486- 5p overexpression 
increases cells’ sensitivity to radiation and accumulation of DBS in 
MCF7 cells. A, Clonogenic assay on MCF7 irradiated with 0, 1, 3 
or 10 Gy 24- h post- transfection with control pSP65/U1, pSP65/
U1- miR- 381- 3p or pSP65/U1- miR- 486- 5p, n = 3. The relative 
surviving fraction of each experimental group was calculated as 
the plating efficiency for each radiation dose (1, 3 and 10 Gy), with 
respect to the sham- irradiated sample. For every experimental 
group it is indicated as the mean value of the relative surviving 
fraction ± SD. Statistical significance was assessed according to 
a 2- tailed Student's t test, *P < .05; **P < .01. B, Representative 
western blotting image of γH2AX levels of cell lysate of transfected 
and irradiated MCF7 cells; 24 h after transfection with pSP65/U1 
or pSP65/U1- miR- 486- 5p MCF7 cells are exposed to 0 or 6 Gy of 
X- rays and irradiated samples are collected after 4, 8, 24 or 36 h. C, 
Relative quantification of γH2AX levels in western blotting analysis, 
n = 3. Data are represented as the mean ± SD of γH2AX levels 
relative to total H2AX. Statistical significance was determined using 
2- way ANOVA, *P < .05
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with respect to sham- irradiated controls, was decreased by almost 
half with respect to the empty vector transfection group (pSP65/
U1). This variation is statistically significant for both miRNAs at 1- Gy 
and 3- Gy doses (P < .01 and P < .05 respectively). A 10- Gy radiation 
dose neutralizes every effect, because the number of cells able to 
proliferate after this treatment is too low to appreciate any differ-
ential sensitivity. To further characterize these observations, we 
tested whether DNA damage was preferentially accumulated in miR- 
486- transfected MCF7 cells by analyzing kinetics of γ- H2AX phos-
phorylation. Figure 4B and C shows that γ- H2AX phosphorylation 
is significantly increased in miR- 486- transfected sham- irradiated 
MCF7 cells, as compared with cells transfected with empty vector. 
This shows that damage accumulates in miR- 486- transfected even 
in the absence of a genotoxic treatment. Irradiation with 6 Gy of 
X- rays, as expected, induced γ- H2AX phosphorylation in both cell 
lines, although accumulation was faster in the miR- 486- transfected 
cell line, which shows a significantly higher phosphorylation level at 
the 8- hour time- point. At later time points, γ- H2AX phosphorylation 
in the miR- 486- transfected line tends to level up with the cells trans-
fected with the empty vector.
3.8 | Analysis of the effects of miR- 381- 3p and miR- 
486- 5p on JARID1B expression in other breast cancer 
cell lines
To understand to what degree the effects of miR- 381- 3p and miR- 
486- 5p can be extended to other breast cancer cell lines, we re-
peated some of the experiments using T47D, another luminal breast 
cancer line, which, as for MCF7, should overproduce JARID1B and 
MDA- MB- 231, a metastatic ER- negative breast cancer cell line, 
which instead should express JARID1B at a lower level because the 
protein seems to reduce its metastatic potential.18
The western blot in Figure 5A shows that, indeed, T47D ex-
presses JARID1B protein at a level very similar to MCF7, while the 
band is barely detectable in the MDA- MB- 231 lane. Next, we looked 
at the expression of the 2 miRNAs. MiR- 381- 3p was undetectable in 
all 3 cell lines (not shown). Interestingly, MDA- MB- 231 cells express 
approximately 4- fold higher levels of miR- 486- 5p as compared with 
MCF7 (Figure 5B), suggesting that the miRNA might be involved in 
downregulation of JARID1B in this cell line. In support of this hypoth-
esis, MDA- MB- 231 cells accumulate JARID1B mRNA at a level com-
parable to MCF7, while it is at least 2- fold higher in T47D (Figure 5C).
Next, we monitored the effects of transfecting T47D cells with 
the 2 miRNAs on the levels of JARID1B protein. As shown in Figure 
S4, transfection with miR- 381- 3p and miR- 486- 5p leads to a signifi-
cant reduction of the protein but only at 48 hours from transfection. 
This delay in the decrease of the protein could be due to the higher 
amount of JARID1B mRNA present in the T47D cells compared to 
the MCF7. We also tested the effects of miRNAs on T47D radiosen-
sitivity using a clonogenic assay (Figure S5). We detected a mild ef-
fect for miR- 486- 5p, while miR- 381- 3p did not show any effect. This 
limited action could be explained by the delayed decline of JARID1B 
F IGURE  5 Expression of JARID1B protein and mRNA and 
of miR- 486- 5p in different human breast cancer cell lines. A, 
Representative western blotting image of JARID1B protein levels 
in the indicated breast cancer cell lines. B, Real time RT- PCR 
quantitation of miR- 486- 5p in the indicated breast cancer cell 
lines. The histogram reports the amounts relative to the U6 
endogenous calibrator. Data are the average of 3 experiments; SD 
is indicated. C, Real- time RT- PCR quantitation of JARID1B mRNA 
in the indicated breast cancer cell lines. The histogram reports the 
amounts relative to the GADPH endogenous calibrator. Data are 
the average of 3 experiments; SD is indicated
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abundance. The same reason could explain the absence of signifi-
cant effects of both miRNAs on the cell cycle kinetics (Figure S6).
4  | DISCUSSION
The JARID1 subfamily of HDM is the only group of enzymes able 
to remove the H3K4me3 mark, which was proposed to have an es-
sential role in regulating gene transcription. However, their expres-
sion in adult tissues is quite low and differentiated among members: 
JARID1A is probably the only member that is broadly expressed. The 
other members show instead limited and tissue- specific expression, 
suggesting precise roles in gene regulation. However, it is now clear 
that JARID1B is highly expressed during development, especially in 
mammalian embryonic stem cells and zygotes. Emerging evidence 
is supporting a role for JARID1 enzymes in regulating H3K4 meth-
ylation dynamics at the level of broad non- canonical H3K4me3 
domains during zygote genome activation,39,43,44 and cell fate and 
self- renewal genes in embryonic stem cell differentiation and re-
programming.45-48 These observations suggest that active reshap-
ing the of H3K4me3 pattern of the human epigenetic landscape is 
mostly performed in highly dynamic epigenomes, such as those of 
early developmental stages, rather than in somatic differentiated 
cells, providing principles for the explanation of such low levels of 
JARID1 enzymes found in adult tissues. However, their role in regu-
lating processes as proliferation, pluripotency and differentiation are 
still to be fully addressed, as we are now beginning to understand 
that their transcriptional role is far more complex than previously 
thought.
Moreover, these speculations are not in contrast with what is 
observed in the context of cancer cells: like other epigenetic mod-
ifiers such as EZH2 and DNMT3B, JARID1B is found to be mainly 
expressed in developmental stages or in cancer (as was confirmed 
by the bioinformatic analysis presented in this work, see Table 1). 
This is probably due to their role in shaping epigenetic features 
that regulate the global cell transcriptome: alterations in the ex-
pression of epigenetic modifiers in somatic cells might lead to an 
unnecessary epigenetic plasticity that could eventually facilitate de- 
differentiation, which, in turn, is a necessary step towards neoplastic 
transformation.
In this work, we confirmed that JARID1B is transcriptionally gen-
erally upregulated in breast cancer. We show a general downregula-
tion of miR- 381- 3p and miR- 486- 5p in breast tumors, proving that 
they are both able to target JARID1B 3′UTR region and to efficiently 
repress its translation into protein. These observations assume 
even more importance if we consider that miR- 486- 5p is the most 
downregulated miRNA of the whole breast cancer transcriptome, 
its expression being almost completely shut down. Moreover, miR- 
381- 3p expression level, which is more variable in cancer samples, 
appears to be positively correlated to patients’ survival. Another 
miRNA targeting JARID1B (mir- 137, Ref. 37) was recently found 
downregulated in breast cancer cells, confirming that shutdown of 
post- transcriptional repression by miRNAs is crucial in order to allow 
overexpression of JARID1B. The strong downregulation of SMYD1 
histone methylase which we observed in cancer tissues (Table 1) also 
points to the relevance of the H3K4me3 levels control for breast 
cancer cells (Figure 6).
Indeed, here we show that miRNA- mediated repression of JARID1B 
translation induces DNA damage accumulation, as revealed by moni-
toring the level of phosphorylated γ- H2AX, and causes an enhanced 
sensitivity to radiation- induced cell death, supporting emerging evi-
dence depicting this HDM as a key regulator of cancer cells resistance 
to genotoxic damage. Very similar effects were recently shown by in-
hibiting the catalytic activity of HDM UTX, specific for H3K27 in other 
cancer cell lines, including the MDA- MB- 231 breast cancer line.49 
Obviously, these observations suggest a straightforward biomedical 
application in cancer therapy: targeting JARID1B by microRNAs could, 
in principle, sensitize cells to radiation- induced cell death.
Moreover, we observed that this JARID1B post- transcriptional 
downregulation determines alteration of the expression of its 
F IGURE  6 Graphic summary of the 
dysregulation of H3K4 tri- methylation 
observed in breast cancer cells and of the 
putative biological effects
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regulatory target gene BRCA1 and cell cycle alterations (G1/G0 
population increase and S population decrease) potentially related 
with it. This gene represents an emblematic trait d'union that ties 
together the emerging role of JARID enzymes in DDR and their al-
ready known role in transcription regulation. JARID1B seems to act 
as both a negative regulator of a DDR factor (BRCA1) and as a pos-
itive factor itself, for DNA repair. Thus, its role cannot be limited to 
that of an oncogene or a tumor suppressor but probably depends 
on the context in which it is found. Certainly, molecular insights on 
chromatin modifications required for efficient DSB repair will be key 
to understand the role of JARID1B in cancer.
Finally, it is worth noting that the almost 3- fold reduction in 
JARID1B protein abundance that we showed in MCF7 miR- 486- 
transfected cells does not cause an evident increase of H3K4 tri- 
methylation in bulk chromatin. This observation suggests that in 
these cells JARID1B overexpression is not strictly required to main-
tain a general low level of histone tri- methylation in the genome but 
is rather important for regulating the expression of specific genes (ie 
BRCA1) and for efficient DNA repair.
The expression of both miRNAs appears to be downregulated 
not only in tumors but also in luminal breast cancer cell lines. MiR- 
381- 3p expression is not detectable not only in MCF7 but also in 
T47D breast cancer lines, while miR- 486- 5p is much more expressed 
in the metastatic ER- negative MDA- MB- 231 breast cancer cell line, 
which poorly expresses JARID1B compared to the 2 luminal breast 
cancer lines. This suggests a possible involvement of miR- 486- 5p in 
the downregulation of JARID1B in this cell line which shows levels 
of mRNA similar to MCF7 but much lower levels of protein. In T47D, 
JARID1B appears to be less responsive than MCF7 to transfection 
with the 2 miRNAs, showing a delayed reduction of the protein 
abundance. This could be due to a less favorable ratio between miR-
NAs and JARID1B mRNA, which in these cells is at least 2- fold more 
abundant. Stoichiometry between miRNAs and mRNAs has often 
been shown to be crucial for effectiveness of repression.
In conclusion, JARID1B overexpression in human breast can-
cer tissues correlates with downregulation of miRNAs targeting its 
mRNA. In human MCF7 breast cancer cell line a causal relationship 
between the 2 phenomena is demonstrated. Moreover, in this can-
cer cell line, miRNAsinduced JARID1B downregulation, although not 
changing the level of bulk chromatin H3K4 tri- methylation, causes 
hypersensitivity to genotoxic damage, BRCA1 de- repression and cell 
cycle alterations. Although the case of T47D cell line shows that re-
sponsiveness to miRNA action could be dependent on the strength 
of transcriptional regulation, and its balance with miRNA abundance, 
these results shed light on JARID1B post- transcriptional regulation 
and open the way for possible therapeutic use of these miRNAs and/
or chemical inhibitors of JARID enzymes in those cancers in which 
they have a primary role.
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